686 Results

People

  1. Giralt
    Giralt
  2. Usmani
    Usmani
  3. Landgren
    Landgren
  4. Lesokhin
    Lesokhin
  5. Landau
    Landau
  6. Mailankody
    Mailankody
  7. Hassoun
    Hassoun
  8. Hultcrantz
    Hultcrantz
  9. Shah
    Shah
  10. Shah
    Shah

Groups

  1. Department of Medicine (425)
  2. Hematologic Malignancies, Division of (378)
  3. Center for Hematologic Malignancies (353)
  4. Myeloma (190)
  5. Hematologic Malignancies Research (156)
  6. Bone Marrow Transplant (145)
  7. Survivorship Research (127)
  8. Sloan Kettering Institute Postdocs (86)
  9. GSK Faculty (76)
  10. Epidemiology and Biostatistics (65)
  1. "multiple myeloma"
Formats
  1. Journal Article (519)
  2. Review (86)
  3. Research Letter (23)
  4. Editorial (17)
  5. Meeting Abstract (15)
  6. Book Section (10)
  7. Correspondence (7)
  8. Guidelines (6)
  9. Conference Paper (2)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (425)
  2. Hematologic Malignancies, Division of (378)
  3. Center for Hematologic Malignancies (353)
  4. Myeloma (190)
  5. Hematologic Malignancies Research (156)
  6. Bone Marrow Transplant (145)

More Groups

People
  1. Sergio Giralt (95)
  2. Saad Usmani (77)
  3. Carl Landgren (76)
  4. Alexander Lesokhin (66)
  5. Heather Landau (55)
  6. Sham Mailankody (55)

More People

Years
  1. 2025 (34)
  2. 2024 (83)
  3. 2023 (85)
  4. 2022 (49)
  5. 2021 (25)
  6. 2020 (47)

More Years

Publications
  1. Blood (37)
  2. Clinical Lymphoma, Myeloma and Leukemia (34)
  3. Biology of Blood and Marrow Transplantation (33)
  4. Leukemia and Lymphoma (21)
  5. Blood Cancer Journal (20)
  6. British Journal of Haematology (20)

More Publications

Publishers
  1. Elsevier Inc. (124)
  2. Nature Publishing Group (84)
  3. American Society of Hematology (48)
  4. Springer (34)
  5. John Wiley & Sons (30)
  6. Taylor & Francis Group (26)

More Publishers

Results (686)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
    Research Letter

    Mohan, M.; Janz, S.; Brazauskas, R.; Dwinell, M. B.; Teng, B. Q.; Yun, G.; Dong, J.; Pasquini, M. C.; Giralt, S.; Landau, H.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Delivery of therapeutic RNA to the bone marrow in multiple myeloma using CD38-targeted lipid nanoparticles
    Journal Article

    Tarab-Ravski, D.; Hazan-Halevy, I.; Goldsmith, M.; Stotsky-Oterin, L.; Breier, D.; Naidu, G. S.; Aitha, A.; Diesendruck, Y.; Ng, B. D.; Barsheshet, H.; more...
    Advanced Science (2023)

    Fulltext@MSK | Save
  • Efficacy, safety, and cost of mobilization strategies in multiple myeloma: A prospective, observational study
    Research Letter

    Dhakal, B.; Zhang, M. J.; Burns, L. J.; Tang, X.; Meyer, C.; Mau, L. W.; Nooka, A. K.; Stadtmauer, E.; Micallef, I. N.; McGuirk, J.; more...
    Haematologica (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel
    Review

    Raje, N.; Anderson, K.; Einsele, H.; Efebera, Y.; Gay, F.; Hammond, S. P.; Lesokhin, A. M.; Lonial, S.; Ludwig, H.; Moreau, P.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Driving CARs to new places: Locally produced BCMA CAR T cells to treat multiple myeloma
    Editorial

    Sjöstrand, M.; Sadelain, M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • Global disparities in patients with multiple myeloma: A rapid evidence assessment
    Journal Article

    Mateos, M. V.; Ailawadhi, S.; Costa, L. J.; Grant, S. J.; Kumar, L.; Mohty, M.; Aydin, D.; Usmani, S. Z.
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: A CIBMTR analysis
    Journal Article

    Ragon, B. K.; Shah, M. V.; D’Souza, A.; Estrada-Merly, N.; Gowda, L.; George, G.; de Lima, M.; Hashmi, S.; Kharfan-Dabaja, M. A.; Majhail, N. S.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • A multicenter phase II, double-blind, placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 trial
    Journal Article

    Bashir, Q.; Nishihori, T.; Pasquini, M. C.; Martens, M. J.; Wu, J.; Alsina, M.; Anasetti, C.; Brunstein, C.; Dawson, P.; Efebera, Y.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders
    Review

    Shah, U. A.; Parikh, R.; Castro, F.; Bellone, M.; Lesokhin, A. M.
    Leukemia (2023)

    Fulltext@MSK | Save